Lantheus Investor Presentation 2024

Lantheus, the leading radiopharmaceutical-focused company, presents its September 2024 investor deck highlighting its commitment to enabling clinicians to find, fight, and follow disease. The presentation includes forward-looking guidance, strategic partnerships with POINT Biopharma and Perspective Therapeutics, and expansion of its portfolio including PYLARIFY, DEFINITY, and clinical candidates MK-6240, PNT2002, and PNT2003.